Technical Analysis for REDIF - Redhill Biopharma Ltd

Grade Last Price % Change Price Change
grade C 0.65 -17.72% -0.1400
REDIF closed down 17.72 percent on Friday, August 9, 2019, on 64 percent of normal volume. The bears made the stock sink to a new 52-week low.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent N/A N/A N/A
See historical REDIF trend table...

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 0.00%
Narrow Range Bar Range Contraction 0.00%
New 52 Week Low Weakness 0.00%
Gapped Down Weakness 0.00%
Volume Surge Other -17.72%
Gapped Up Strength -17.72%
Narrow Range Bar Range Contraction -17.20%
Gapped Up Strength -17.20%
Narrow Range Bar Range Contraction -15.58%
Gapped Down Weakness -15.58%

Older signals for REDIF ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
RedHill Biopharma Ltd., a specialty biopharmaceutical company, focuses on the development and commercialization of late clinical-stage drugs for the treatment of gastrointestinal diseases. It commercializes and promotes gastrointestinal products in the United States. The company's pipeline includes various drug candidates that are in advanced clinical development stages, including three Phase III-stage programs. Its principal clinical-stage development programs comprise TALICIA (RHB-105) for Helicobacter pylori infection; RHB-104 for Crohn's disease; RHB-204 for nontuberculous mycobacteria infections; BEKINDA (RHB-102) for acute gastroenteritis and gastritis and diarrhea-predominant irritable bowel syndrome; YELIVA (ABC294640) for cholangiocarcinoma, as well as targeting other oncology, inflammatory, and gastrointestinal indications; RHB-106, an encapsulated bowel preparation; and RHB-107 for cancer and inflammatory gastrointestinal diseases. The company was founded in 2009 and is headquartered in Tel Aviv, Israel.
Medicine RTT Medical Specialties Cancer Clinical Medicine Biopharmaceutical Diarrhea Crohn's Disease Irritable Bowel Syndrome Gastritis Gastrointestinal Diseases Gastrointestinal Tract Inflammatory
Is REDIF a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 0 bearish and 5 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Indicator Value
52 Week High 0.97
52 Week Low 0.65
Average Volume 1,562
200-Day Moving Average 0.0
50-Day Moving Average 0.0
20-Day Moving Average 0.0
10-Day Moving Average 0.0
Average True Range 0.0
ADX 0.0
+DI 0.0
-DI 0.0
Chandelier Exit (Long, 3 ATRs ) N/A
Chandelier Exit (Short, 3 ATRs ) N/A
Upper Bollinger Band 0.0
Lower Bollinger Band 0.0
Percent B (%b) 0.0
BandWidth 0.0
MACD Line 0.0
MACD Signal Line 0.0
MACD Histogram 0.0
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.6500
Resistance 3 (R3) 0.6500 0.6500 0.6500
Resistance 2 (R2) 0.6500 0.6500 0.6500 0.6500
Resistance 1 (R1) 0.6500 0.6500 0.6500 0.6500 0.6500
Pivot Point 0.6500 0.6500 0.6500 0.6500 0.6500
Support 1 (S1) 0.6500 0.6500 0.6500 0.6500 0.6500
Support 2 (S2) 0.6500 0.6500 0.6500 0.6500
Support 3 (S3) 0.6500 0.6500 0.6500
Support 4 (S4) 0.6500